March 2024
The global cardiac biomarkers market size was USD 18.50 billion in 2023, calculated at USD 21.20 billion in 2024 and is expected to be worth around USD 82.99 billion by 2034. The market is slated to expand at 14.62% CAGR from 2024 to 2034.
The global cardiac biomarkers market size is expected to be worth USD 21.20 billion in 2024 and is anticipated to reach around USD 82.99 billion by 2034, growing at a solid CAGR of 14.62% over the forecast period 2024 to 2034. The North America cardiac biomarkers market size reached USD 7.59 billion in 2023. The rising demand for adequate diagnosis and monitoring of heart attack, stroke, or any heart disease is projected to accelerate the growth of the cardiac biomarkers market.
The U.S. cardiac biomarkers market size was exhibited at USD 5.69 billion in 2023 and is projected to be worth around USD 25.83 billion by 2034, poised to grow at a CAGR of 14.74% from 2024 to 2034.
North America dominated the cardiac biomarkers market in 2023. The main reason for market growth is the increasing number of heart disease cases in this region. But at the same time, North America has developed healthcare facilities and demandable biomarkers to treat, monitor, and diagnose heart conditions.
Asia Pacific is expected to witness the fastest growth in the cardiac biomarkers market during the forecasted years. Asia Pacific is known for its extensive laboratory and advanced research and development program. APFCLM (Asia-Pacific Federation for Clinical Biochemistry and Laboratory Medicine) is an Asian-Pacific association of 18 member countries that promotes a variety of scientific/educational activities. Most cardiac tests are ordered in emerging countries, such as India, China, Vietnam, and Indonesia.
Cardiac biomarkers are intracellular macromolecules released into the bloodstream when the heart is damaged or under stress. Rising heart enzyme levels help to reveal acute coronary syndrome or ischemia. The use of the cardiac biomarkers market services has extensively increased in the past decade and provides more successful results in the diagnosis of myocardial cell injury or heart failure.
The biomarkers used in the mid-20th century (Aspartate transaminase (AST) and Lactate dehydrogenase) are not clinically suitable in present days however, they are now replaced with more sensitive and specific biomarkers. It is expected for biomarkers to evolve to provide a substantial understanding of the pathogenesis of cardiac diseases.
How is AI changing the Cardiac Biomarkers Market?
The evolution of the cardiac biomarkers market and the result of prediction has integrated several multi-omics such as genomics, metabolomics, proteomics, and other omics technologies. The primary application of AI in multi-omics is to identify the biomarkers for cardiovascular risk, integrate multi-omics data to depict patient subsets with molecular characteristics and prepare for personalized medicine.
This personalized solution is a promising step towards improving the accuracy of cardiovascular risk prediction and developing precision medicine in the cardiac biomarkers market. By incorporating such innovative approaches and continuous expansion of the potential genomics and AI, the future is anticipated to have a proactive, personalized approach to CVD management, resulting in improving patient outcomes globally.
Report Coverage | Details |
Market Size by 2034 | USD 82.99 Billion |
Market Size in 2024 | USD 21.20 Billion |
Market Growth Rate from 2024 to 2034 | CAGR of 14.62% |
Largest Market | North America |
Base Year | 2023 |
Forecast Period | 2024 to 2034 |
Segments Covered | Type, Application, End-use, and Regions |
Regions Covered | North America, Europe, Asia-Pacific, Latin America and Middle East & Africa |
Rising heart disease cases
The primary causes of heart disease are genetics, unhealthy lifestyle, high blood pressure, high cholesterol, smoking, and many more. Cardiac biomarker provides numerous advantages in lowering the occurring cases by screening the damaged heart and other problems, predicting the result for various heart conditions, monitoring the efficiency of heart medications and heart surgery process, and diagnosis of heart conditions led by symptoms such as chest pain and shortness of breath.
Lack of standardisation
The main drawback of cardiac biomarkers market is the lack of standardization. Different laboratories are using different methodologies for the measurement of biomarkers, which is leading to inconsistent results. Currently, there is a lack of standardization between different assays and variations of concentration. Therefore, it is hard to compare. The hindrance in comparing the study's data and the institution's complex is impacting the worldwide adoption of cardiac biomarkers in clinical application.
Price structure and availability
In the healthcare setting, biomarker assays are extremely expensive and not feasible for routine use. The availability and ease of access depend on different regions and healthcare facilities in the cardiac biomarkers market. This causes social inequality among patients and their diagnosis.
In the future, sensitivity and specificity will no longer be an issue when diagnosing heart disease. The increased sensitivity by assays is costly, which decreases the diagnostic specificity. Therefore, that problem is expected to be resolved in the future. New biomarker identifications will be implemented to understand the complex cardiac pathophysiology. The cardiac biomarkers market will be enhanced in the foreseeable future as it is not specific enough to be a cardiac biomarker. Multi-biomarker approaches, such as tissue-specific markers, will be added for diagnosis, which will be helpful.
The Troponin segment dominated the cardiac biomarkers market in 2023. Troponin protein is the most used biomarker. It is highly sensitive compared to the other protein biomarkers. The sensitivity is useful for diagnosis, monitoring, and prediction of heart attacks. Current American Heart Association (AHA) guidelines state that troponin is the best biomarker for finding a heart attack. It also warns against using other biomarkers such as CK, CK-MB, and myoglobin. Due to their being less specific for the heart, it may cause complicacy with skeletal muscle injury. The extensive use of troponin is observed in hospitals, emergency rooms, and similar healthcare settings.
The BNP and NT-proBNP segment is expected to grow at the fastest rate in the cardiac biomarkers market over the forecast period. BNP and NT-proBNP are natriuretic peptide proteins that are produced by the heart. They are commonly used to confirm or eliminate heart failure. Although they are usually used to recognize heart failure, an increased number of people with ACS has indicated an increased risk of recurrence in the symptoms. If the result of Brain Natriuretic Peptide (BNP) is greater than 100 pg/mL, it indicates abnormality and the presence of heart failure. The higher the result, the greater the severity.
The acute coronary syndrome segment accounted for the largest share of the cardiac biomarkers market in 2023. It is a collaborative condition that either immediately stops or severely slows down the blood flow to the heart muscle. Due to the hindrance in blood flow to the heart, the heart muscles become damaged, causing heart attacks and angina. ACS requires emergency medical care at the healthcare facility. Some primary tests for ACS are an electrocardiogram (ECG or EKG) and blood test with the help of a cardiac biomarker. The testing helps the healthcare professional to provide the patient with the right diagnosis.
The other segment is expected to grow rapidly in the cardiac biomarkers market during the forecasted years. The other segment includes myocardial infarction, congestive heart failure, pulmonary embolism, and non-ST non-ST-elevation myocardial infarction (NSTEMI). Among all, myocardial infarction is expected to grow at the fastest rate. Myocardial infarction is silent and undetected; the events may lead to hemodynamic deterioration and sudden death. For instance, In the United States, the majority of myocardial infarctions are due to underlying coronary artery disease.
The laboratory testing segment contributed the biggest share of the cardiac biomarkers market in 2023. The laboratory testing is either performed at the hospital facility or a private laboratory. These places can test a high volume of samples in one sitting. Laboratory testing provides a reliable and precise result of the health problem while other tests provide a general idea. It takes up to 24 hours or more to show results. These tests are conducted considering federal regulatory standards and go through strict criteria before presenting them to the physician.
The point-of-care testing segment is anticipated to have the fastest growth rate in the cardiac biomarkers market during the forecasted years. A point-of-care test is also known as near-patient resting; it provides doctors with accurate, real-time, and quick laboratory-quality diagnostic results. In POCT, portable analyzers simplify the diagnostic process to ensure that patients receive the care they need. This test is not always accurate. They frequently show errors depending on the testing device used. As these tests can be conducted one test at a time, this method is suitable for at-home service.
Segments Covered in this Report
By Type
By Application
By End-use
By Geography
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
March 2024
October 2023
August 2024
August 2024